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Beta2-nsicroglobulin deposition in bone in chronic renal failure. Re-
cently, there have been reports of beta2-microglobulin (132m) related
amyloid deposition in perineural and periarticular tissues in patients
receiving long-term hemodialysis, but it has been rarely described in
bone. We, therefore, examined previously obtained bone biopsy spec-
imens in patients receiving long-term hemodialysis to determine the
prevalence of /32m deposition in bone and to assess the relationship
between /3m deposits and bone histomorphometry. We found 2m
deposits in bone in 8% of 224 patients examined. Bone deposition of
2m was absent in patients who were on dialysis for less than six years,
but was present in 19% who dialyzed longer than 10 years. p2m deposits
were fOund in specimens from the iliac crest, femoral bone, tibia,
vertebra and rib. In the iliac crest /32m deposition was loéalized pre-
dominantly to the periosteum. Among these patients with f32m in iliac crest
periosteum, 62% had suffered a femoral neck fracture compared to only
4% of matched patients who had negative staining for f32m in the iliac
crest (P < 0.001). Histologically; osteitis fibrosa seemed more common
in patients positive for /3gm than in patients negative for /32m deposition
We conclude that $2m deposition in bone is common in uremic patients
who haye received hemodialysis longer than 10 years. The high
prevalence of femoral neck fracture in patients with j32m localized to the
periosteum of the iliac crest suggests that this involvement may be
useful to predict susceptibility to femoral fracture.
Recently there have been reports characterizing the amyloi-
dosis that occurs in patients treated with long-term hemodialy-
sis. Beta2-microglobulin (j32m) has been identified as the major
component of amyloid fibrils by biochemical and immunologic
studies [1—41. While amyloid deposits are found most frequently
in perineural, periarticular and articular locations [5—10], it is
unknown why amyloid preferentially deposits in these tissues.
Less well studied are the cystic bone lesions thought to be
secondary tà local amyloid deposition [5, 6, 9—13], the likely
result of f32m accumulation [8, 14].
/32m, an 11,800 dalton protein may be an important determi-
nant of bone cell function. In vitro studies have shown in one
study that f32m is produced in cultured bone cells [15] and is
mitogenic in osteoblast enriched populations [15]. In another
study [16], however, /3m inhibited osteoblastic mineralization,
while collagen synthesis was maintained. Whether the accumu-
lation of j32rn in bone contributes to the variable histology of
renal osteodystrophy is unknown. However, the high circulat-
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ing concentrations of /32m in dialysis patients (40 to 50 g/ml) [1]
could substantially affect osteoblast function and consequently,
bone turnover.
The purpose of the present study was to determine the
prevalence of amyloid deposition in bone of patients receiving
long-term hemodialysis and to ascertain whether the presence
of /32m in bone correlates with bone histomorphometry.
Methods
Materials
Bone specimens were obtained from 224 patients (140 males,
84 females; age range, 14 to 75 years) who had received
hemodialysis for a mean (± SD) of 9 4 years (range, 1 to 22
years). All patients had received thrice weekly hemodialysis
using cuprophane membranes for most of their dialysis experi-
ence. None had multiple myeloma or primary amyloidosis as
the underlying cause of renal failure. Overall, there were 246
bone specimens for evaluation: 234 biopsies from the iliac crest,
7 from the femoral head in patients with femoral neck fracture,
1 from the tibia (biopsy of pathologic fracture), and 2 each from
vertebra and rib (autopsy specimens). The iliac crest biopsies
were obtained from patients being evaluated for renal osteodys-
trophy at several institutions throughout the United States
between 1985 and 1988. The femoral heads were obtained from
all the patients in three dialysis programs (total patient popula-
tion approximately 600) who required femoral prostheses in a
five-year period.
Immunohistochemjcal studies
Methyl methacrylate-embedded, undecalcified 5 s-thick sec-
tions were stained with alkaline Congo red and were examined
by conventional and polarized light microscopy. Immunohisto-
chemical studies were made with the peroxidase-antiperoxidase
method [17]. Methyl methacrylate-embedded, 3 j.-thick sec-
tions from Congo red-positive bone biopsy specimens were
attached to slides by Tissue-Tack (Polysciences, mc) and then
treated in alcoholic sodium hydroxide for 10 minutes, and
washed in absolute ethanol for 10 minutes. The sections were
dipped in a 1% solution of hydrogen peroxide in absolute
methanol for 30 minutes to inhibit endogenous peroxidase
activity and washed three times for five minutes in phosphate-
buffered saline. The non-specific reactivity of the secondary
antibody was blocked by applying a 1% goat or donkey serum
solution in phosphate-buffered saline supplemented With 4%
bovine serum albumin for 15 minutes. The block solution was
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poured off the slides and the sections were incubated overnight
at 4°C in a humid chamber with rabbit antihuman antisera using
the following dilutions: 1:1000 for /32-microglobulin, 1:500 for
amyloid A component, 1:1000 for kappa and lambda immuno-
globulin light chain antibody and goat antihuman antisera, 1:500
for prealbumin (Sigma Chemical Co., St. Louis, Missouri,
USA). The primary antibody was washed off with phosphate-
buffered saline, as described above. The secondary goat anti-
rabbit IgG or donkey antigoat IgG was applied at a a dilution of
1:200 for 60 minutes at room temperature and then rabbit or
goat peroxidase-antiperoxidase antiserum at 1:300 for 60 min-
utes at room temperature. Visualization of the bound peroxi-
dase was achieved with the diaminobenzidine-H202 reaction for
five minutes. As negative controls, tissue sections of kidney
from patients with proven AA, AL and Aprealbumin amyloi-
dosis (provided by Dr. T. Shirahama, Boston University,
Massachusetts, USA) were used as comparisons. A strict
positive control was not done as we did not have the capability
to analyze tissue for 132m biochemically. However, in one
patient with extensive amyloid seen on both Congo red and f32m
immunohistochemical stains, electron microscopic studies were
done. At five different sites that were positive by both staining
techniques, the unique curvilinear fibrils said to be character-
istic of f32m amyloid [21 were seen.
Bone histotnorphometry
Histomorphometric analysis of Goldner stained sections was
performed as previously reported [18]. The following classifi-
cations were made: osteitis fibrosa, if bone formation was
normal or increased and there was significant marrow fibrosis;
osteomalacia, if bone formation was below normal and there
was an excess of unmineralized osteoid; mixed disease, if
excess osteoid and marrow fibrosis were present; aplastic bone
disease, if bone formation was below normal and osteoid area
was normal or reduced; or mild hyperparathyroid disease, if
bone formation and osteoid area were normal but osteoid
covered surfaces were increased. Separate sections were also
stained with aurintricarboxylic acid for the identification of
aluminum [19] and Prussian blue for the detection of iron.
The Chi-square test was used for statistical analysis and a P
value <0.05 was considered significant.
Results
Congo red positive amyloid deposits in bone, as identified by
apple-green birefringence under polarized light, were found in
19 of the 224 patients (Figs. 1A, B and 2). The mean (± SD) age
of affected patients (9 males and 10 females) was 55 9 years
(range, 34 to 69 years) and the mean duration of hemodialysis
was 13 4 years (6 to 18 years). Immunohistochemical studies
revealed that all the amyloid deposits reacted with anti-/32m
antibody (Figs. 1C, 3, and 4) and none reacted with antihuman
AA, AL or Aprealbumin antibodies. None of the control kidney
sections of AA, AL and Aprealbumin types of amyloid stained
for anti-132m.
Figure 5 shows the prevalence of f32m related amyloid in bone
as a function of dialysis duration. /32m deposits were not present
in 45 patients who had received dialysis for less than six years,
but were found in 3 of 94 patients treated for 6 to 10 years and
in 16 of 85 patients treated longer than 10 years.
Table 1 summarizes the histologic location of f32m related
Fig. 1. Serial sections of femoral bone from a dialysis patient. A.
Congo red stain. Amyloid deposits (arrow) are seen in the superficial
articular cartilage (C) (xl 15). B. The same area under polarized light.
Congo red stained amyloid deposits demonstrate green birefringence
(xl 15). C. Immunohistochemical staining with anti-132m. Amyloid
deposits stain brown for /32m (xl 15).
amyloid in bone. /32m was identified in 17 (7%) of the 234 bone
specimens from the iliac crest (periosteum in 16, cartilage in 1
and bone marrow in 2), in six of seven femoral bone specimens
(synovium in 4, superficial articular cartilage in 3, trabecular
bone in 1 and bone marrow in 5) and in one specimen from the
tibia (involving the synovium, cortical bone and bone marrow).
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FIg. 3. Iliac crest bone biopsy stained with anti-132m and hematoxylin
counterstain. /32m deposits (arrows) are located in the iliac periosteum
(P) (xl 15). C, cortical bone; M, marrow.
Sections from vertebra and rib had f32m deposits in the perios-
teum only. Among the six patients with 2m deposition in the
femoral bone, there were four who also had iliac crest biopsies,
three of which were positive for f32m in the periosteum.
Table 2 shows the percent of tissue area occupied by amy-
bid. The iliac crest contained relatively small amounts of
amyloid while the other tissues contained considerably more.
This is not surprising since the other specimens were obtained
from areas with symptoms while none of the patients had
symptoms referable to the iliac crest. There was no difference in
dialysis duration between the patients with femoral fracture (X
14 years, range 7 to 20) and iliac crest biopsy (X 15 years, range
8 to 20). Patients with biopsies from other sites had been on
dialysis for 6, 16 and 23 years when their bone was obtained
from the tibia, vertebra and rib, respectively.
Shown in Table 3 is the relationship between f32m deposition
in the periosteum of iliac crest and the prevalence of femoral
neck fracture in matched dialysis patients. Among the 13
Fig. 5. The prevalence of /32m related amyloid in bone as a function of
hernodia!ysis duration.
patients with /32m deposition in the iliac crest periosteum, 8(62%) had a femoral neck fracture. In contrast, only 1 of 25
patients who were matched for age, sex, and dialysis duration
and who were negative for 2m had sustained a femoral neck
fracture (P < 0.001). Cortical thickness in the eight patients
with femoral fracture measured 338.6 139.9 , while in 19 of
the 25 patients who were controls (in 6 patients cortex was
removed for chemical measurements) it measured 437 378.5
(mean SD, P = NS). Cancellous bone volume also did not
differ.
Because recent reports have suggested an association be-
tween aluminum and/or iron accumulation and dialysis-related
amyloid deposition, stains for aluminum and iron were per-
formed in all amyloid positive bone specimens and compared to
67 amyloid-negative bone specimens obtained from patients
who were matched for age, sex, and dialysis duration (Table 4).
Aluminum on the bone surface was present in 92% of amyloid
positive specimens and bone marrow iron was present in 77%.
In the amyboid negative specimens, bone surface aluminum was
Fig. 2. A section under polarized light showing the bone marrow of the
same patient as in Fig. 1. Amyloid deposits (arrow) adjacent to the
bone trabeculae demonstrate green birefringence (x29).
Fig. 4. Bone section from the tibia with anti-132m and methylene blue
counterstain. /32m positive deposits (arrows) appear to invade the
cortical bone (C) from the marrow (M) (polarized light; xl 15).
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Table 1. Histologic sites of 2m related amyloid in bone of dialysis patients
Source of biopsy
'Site of stamed f32m
Periosteum Synovium Cartilage Bone Bone marrow
Iliac crest (17/234) 16 NA 1 0 2
Femoral head (6/7) NA 4 3 1 5
Tibia (1/1) NA 1 NA I I
Vertebra (1/2) 1 NA NA 0 0
Rib (1/2) 1 NA NA 0 0
Numbers in parentheses indicate the number of positive specimens per total number examined. NA, not applicable.
Table 2. Amyloid % of tissue area
Iliac Femoral
crest head Vertebra Rib Tibia
1 0.13
2 0.11
3 0.73 5.40 0.18
4 0.01
5 0.007
6 0.09
7 0.007
8 0.86 0.04
9 0.004
10 0.01
11 0.004
12 0.001
13 0.002
14 0.001
15 0.004
16 0.02
17 0.004 4.83
18 1.62
19 1.61
20 0.43
21 13.38a
22 0.07
a Area of pathologic fracture
present in 94% and bone marrow iron was present in 75%.
Neither metal was found in proximity to the /32m deposits.
Discussion
In patients treated with long-term hemodialysis, amyloid
deposition is preferentially localized to periarticular tissues
[5—10]. Although a few reports [7, 8, 14] have described amyloid
involvement in bone, little is known about the prevalence of
bone amyloid deposition in chronic uremia. In the present
study, we found that amyloid in bone stained exclusively for
/32m and that the periosteum was the predominant location
when /32m was present in the iliac crest. While the deposition of
f32m in bone was not apparent until after five years of hemodi-
alysis, its presence increased in frequency after that time
reaching a prevalence of 19% in patients who had dialyzed
longer than 10 years.
The occurrence of /32m in bone may be much more frequent
than we find in iliac crest biopsies. Although the most common
location to do bone biopsies, the iliac crest may not be a
"favored" location for deposition of this material. It seems
unlikely that we failed to detect (false negative error) any
substantive amount of amyloid since we screened a minimum of
20 mm2 of bone and were able to detect as little as 0.004% of
tissue area of amyloid (0.08 mm2).
Table 3. Relationship between f32m deposition in the iliac periosteum
and the prevalence of femoral fracture in matched dialysis patients
Iliac periosteum Femoral fracture
J32m positive (N = 13) 8 (62%)
132m negative (N = 25) 1 (4%)
a p < 0.001
Table 4. Relationship between f32m deposition in bone and the
location of aluminum and iron deposits
2m deposition
Bone surface
aluminum
Bone marrow
iron
Positive (N = 26) 24 (92%) 20 (77%)
Negative (N = 67) 63 (94%) 50 (75%)
The prevalence of carpal tunnel syndrome, a proven compli-
cation of amyloidosis [5—8] is greater than 50% in patients on
dialysis over 10 years. Thus, our finding of a 19% prevalence in
the iliac crest underestimates the actual incidence of this
systemic illness. A true prevalence can only be established by a
detailed autopsy study. Nonetheless, the demonstration of an
increased frequency of amyloid deposits with time on dialysis
and the apparent relation to femoral fracture are worth noting.
It is possible that amyloid deposition in the iliac crest tells us
more about the severity than the prevalence of this condition.
Until recently, pathological hip fractures in dialysis patients
have been assumed to be secondary to hyperparathyroidism,
aluminum accumulation, or other metabolic abnormalities such
as osteoporosis. The last problem does not appear to be an
important contributor in these patients, since iliac crest bone
volume and cortical thickness did not differ between patients
and controls. Admittedly, osteoporosis may not be well distin-
guished with iliac crest histology.
Our histologic studies demonstrate that when present amy-
bid is diffusely deposited in bone supporting the concept that
extensive deposition may contribute to bone weakness in
specific areas [12, 20], and possibly predispose to fractures. The
finding of amyloid in six of seven femoral specimens from
patients with femoral neck fractures further supports this hy-
pothesis. Interestingly, there was a higher prevalence of femo-
ral fracture in patients with periosteal deposition of /32m in the
iliac crest when compared to matched patients with negative
staining for /32m. It is not clear why f32m preferentially accu-
mulates in periosteal tissue. However, in affected patients the
appearance of 2m in the iliac periosteum may indicate that
substantial amounts of $2m have also accumulated in femoral
bone, thereby increasing the risk for fracture in that location.
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While it is unknown how J32m in bone might relate to fractures,
observations in patients with primary amyloidosis suggest that
localized erosions [21], diffuse demineralization [22], and avas-
cular necrosis due to amyloid deposition in marrow vessels [23],
may all contribute to bone weakness.
We also attempted to assess whether f32m accumulation was
associated with any particular histologic type of renal osteodys-
trophy. There was a suggestion from this analysis of an increase
in high turnover (osteitis fibrosa) and decrease in low turnover
lesions (aplastic, osteomalacic) in the /32m positive patients.
Since /32m has been reported to be mitogenic for osteoblast-like
cells in culture [15], it is possible that it participates with other
osteoblast mitogens such as insulin-like growth factor 1 [24, 25]
and PTH [26] in stimulating osteoblastic proliferation. On the
other hand 2m has also been reported to cause a mineralization
defect (a feature of low turnover lesions) in vitro [161. Thus,
what effect f32m might have on bone cells in vivo is hard to
predict.
Circulating interleukins (IL) may have a role in the pathogen-
esis of dialysis-related f32m deposition. Levels of serum IL-i are
elevated in patients who have received hemodialysis for longer
than 10 years [27]. More recently, it was shown that serum
concentrations of the soluble IL-2 receptor, a 55 kD IL-2
binding protein produced by activated T lymphocytes, are
elevated in hemodialysis patients [28]. f32m and IL-2 receptor
levels in serum rise during hemodialysis, suggesting that the
dialytic procedures itself may cause shedding of these cell-
surface proteins. Moreover, patients with the carpal tunnel
syndrome have higher levels of IL-2 receptor in serum when
compared to patients without clinically evident amyloidosis
[28]. Whether elevated levels of the interleukins are associated
with 132m deposition in bone is unknown. However, it has been
shown that IL-i stimulates cellular proliferation when added to
cultures of osteoblast-like cells [291. Thus, circulating IL-I
when elevated could enhance bone turnover by increasing the
number of active osteoblasts that are capable of forming new
bone.
It has been suggested that aluminum or iron may act to
promote the polymerization of f.2m into amyloid fibrils [30—32].
In our study, aluminum in bone and iron in the bone marrow
were found in most of the bone specimens examined. Neither
metal was found in the same location as the /32m and both
metals were present in patients regardless of whether they had
/32m deposition or not. These data, therefore, suggest that
aluminum and iron deposition are complications of long-term
hemodialysis, similar to f32m deposition, and are probably not
important in the pathogenesis of f32m deposition bone.
Plasma J32m levels have been reported to be lower in patients
treated with high flux dialysis when compared to patients using
cuprophane membranes. The larger sized membrane cut-off
(> 12,000 daltons) and higher flow rates achieved by high flux
dialysis are likely responsible for the increased clearance of
f32m [33—37]. Although j32m levels have not predicted the
occurrence of clinically relevant amyloid deposition [38], long-
term dialysis with polyacrylonitrile membranes appears to be
associated with a lower incidence of amyloid-related problems
when compared to long-term use of cuprophane membranes
[39]. Long-term trials comparing conventional and other high-
flux dialysis membranes should help determine the optimal
dialytic regimen which will prevent f32m amyloidosis.
In conclusion, our results show that /32m deposition in bone is
common in uremic patients who have received hemodialysis
longer than 10 years. The increased prevalence of femoral neck
fracture in patients with 2m in the iliac periosteum suggests
that this site may be helpful in predicting femoral fracture in
high risk patients. While the mechanisms responsible for f32m
deposition are unknown, the presence of aluminum or iron
appears to be unimportant in the bone deposition of f32m.
Because of the possible association of bone f32m and osteitis
fibrosa in our study and the known proliferative effect of f32m in
cells of the osteoblast lineage, it may be that chronically
elevated plasma levels of /32m are involved in promoting high
bone turnover in chronic renal failure. Alternatively, j32m
deposition and PTH elevation may both be consequences of
long-term dialysis and just be coincidentally related.
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